Receptor Binding Activities of Chlorella on Cysteinyl Leukotriene CysLT, Glutamate AMPA, Ion Channels, Purinergic P2Y, Tachykinin NK2 Receptors and Adenosine Transporter

被引:1
作者
Cheng, Fong-Chi [1 ]
Feng, Jin-Jye [1 ]
Chen, Kuo-Hsin [1 ]
Imanishi, Hideyo [1 ]
Fujishima, Masaki [2 ]
Takekoshi, Hideo [2 ]
Naoki, Yo [2 ]
Shimoda, Minoru [3 ]
机构
[1] MDS Pharma Serv Taiwan Ltd, Taipei 112, Taiwan
[2] Sun Chlorella Corp, Shimogyo Ku, Kyoto 6008177, Japan
[3] Tokyo Univ Agr & Technol, Natl Univ Corp, Fuchu, Tokyo 1838509, Japan
关键词
Chlorella; glutamate; ion channels; leukotriene; purinergic (P2Y); receptors; serotonin 5HT(2B); tachykinin NK2; transporter; UNICELLULAR GREEN-ALGAE; INTERNATIONAL UNION; FECAL EXCRETION; RAT-BRAIN; PYRENOIDOSA; AUGMENTATION; FIBROMYALGIA; PHARMACOLOGY; ANTAGONISTS; MECHANISMS;
D O I
10.1002/ptr.2864
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A Chlorella powder was tested in a total of 129 in vitro receptor binding assay systems. The results showed a potent inhibition of this powder on cysteinyl leukotriene CysLT2, and glutamate AMPA in a dose-concentration manner with IC50 mean SEM values of 20 +/- 4.5 mu g/mL and 44 +/- 14 mu g/mL, respectively. Other moderate and weak activities reflected in competitive binding experiments were seen versus adenosine transporter; calcium channel L-type, benzothiazepine; gabapentin; kainate, NMDA-glycine; inositol trisphosphate IP3; cysteinyl CysLT(1), LTB4; purinergic P-2Y; tachykinin NK2; serotonin 5-HT2B and prostanoid, thromboxane A(2). Together, the results suggest that the various inhibitory effects of Chlorella powder in these receptor binding assays could reflect its actions in modulating Ca2+-dependent signal related targets and might be relevant to the mechanisms of its biological effects. These results reveal important potential biochemical activities that might be exploited for the prevention or treatment of several pathologies. From these results, the possible therapeutic usage of the product is discussed. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:43 / 48
页数:6
相关论文
共 47 条
  • [1] International union of pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy
    Abbracchio, Maria P.
    Burnstock, Geoffrey
    Boeynaems, Jean-Marie
    Barnard, Eric A.
    Boyer, Jose L.
    Kennedy, Charles
    Knight, Gillian E.
    Fumagalli, Marta
    Gachet, Christian
    Jacobson, Kenneth A.
    Weisman, Gary A.
    [J]. PHARMACOLOGICAL REVIEWS, 2006, 58 (03) : 281 - 341
  • [2] Gabapentin in the treatment of fibromyalgia - A randomized, double-blind, placebo-controlled, multicenter trial
    Arnold, Lesley M.
    Goldenberg, Don L.
    Stanford, Sharon B.
    Lalonde, Justine K.
    Sandhu, H. S.
    Keck, Paul E., Jr.
    Welge, Jeffrey A.
    Bishop, Fred
    Stanford, Kevin E.
    Hess, Evelyn V.
    Hudson, James I.
    [J]. ARTHRITIS AND RHEUMATISM, 2007, 56 (04): : 1336 - 1344
  • [3] The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo
    Beattie, DT
    Smith, JAM
    Marquess, D
    Vickery, RG
    Armstrong, SR
    Pulido-Rios, T
    McCullough, JL
    Sandlund, C
    Richardson, C
    Mai, N
    Humphrey, PPA
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (05) : 549 - 560
  • [4] The inositol 1,4,5-trisphosphate receptors
    Bezprozvanny, I
    [J]. CELL CALCIUM, 2005, 38 (3-4) : 261 - 272
  • [5] Adenosine and epilepsy: From therapeutic rationale to new therapeutic strategies
    Boison, D
    [J]. NEUROSCIENTIST, 2005, 11 (01) : 25 - 36
  • [6] 5-HT2B receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro
    Borman, RA
    Tilford, NS
    Harmer, DW
    Day, N
    Ellis, ES
    Sheldrick, RLG
    Carey, J
    Coleman, RA
    Baxter, GS
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (05) : 1144 - 1151
  • [7] BOYER JL, 1990, J BIOL CHEM, V265, P13515
  • [8] International union of pharmacology - XXXVII. Nomenclature for leukotriene and lipoxin receptors
    Brink, C
    Dahlen, SE
    Drazen, J
    Evans, JF
    Hay, DWP
    Nicosia, S
    Serhan, CN
    Shimizu, T
    Yokomizo, T
    [J]. PHARMACOLOGICAL REVIEWS, 2003, 55 (01) : 195 - 227
  • [9] Cysteinyl-leukotriene receptor antagonists: Present situation and future opportunities
    Capra, V.
    Ambrosio, M.
    Riccioni, G.
    Rovati, G. E.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2006, 13 (26) : 3213 - 3226
  • [10] Leukotriene A4 hydrolase as a target for cancer prevention and therapy
    Chen, X
    Wang, S
    Wu, N
    Yang, CS
    [J]. CURRENT CANCER DRUG TARGETS, 2004, 4 (03) : 267 - 283